Let’s List All of the Events Impacting Sentiment for Equities…
Insights - The NASDAQ Biotech Index (NBI) ended the week on a low note – just 2 percentage points from giving back the entirety of its gains … Continue Reading
Read NowInsights
A Roundup of this Week’s Market/Biotech Events
Insights - The long-awaited September meeting of the FOMC takes place this coming Thursday. Market participants are unusually attuned to this particular meeting due to the ongoing … Continue Reading
Read Now
Despite Repeat Objections, AcelRx Must Run Another Clinical Trial
Insights - After repeat attempts to convince the U.S. FDA that the company should not be required to run another clinical trial, it appears AcelRx Pharmaceuticals (ACRX) may have finally … Continue Reading
Read NowHere’s a Deal for Your Three-Day Weekend…
Insights - After the last two weeks, everyone’s ready for a 3-day break. August closed out with the S&P 500 down 6%, and the NASDAQ Biotech Index … Continue Reading
Read Now
Amicus Therapeutics Does Some Acquiring of its Own
Insights - Amicus Therapeutics (FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own. Amicus announced early Monday that it will buy … Continue Reading
Read NowMight Ariad Pharma Finally be Bought?
Insights - That was the rumor on anyway, sending shares of Ariad Pharmaceuticals (ARIA) higher by 40% in the Friday trading session. Bloomberg reported at noon on … Continue Reading
Read Now
Finally, Sarepta’s Eteplirsen is Officially in the FDA’s Queue
Insights - The U.S. FDA has filed Sarepta Therapeutics’ (SRPT) eteplirsen New Drug Application, starting the clock on a 6-month review of the drug. The FDA will make an … Continue Reading
Read Now